Inmed announces presentation of inm-755 phase 2 clinical study results at 12th world congress on itch (wci) 2023

Vancouver, british columbia--(newsfile corp. - november 2, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that an abstract describing the phase 2 clinical study of investigational drug inm-755 cannabinol ("cbn") cream for the treatment of symptoms in patients with epidermolysis bullosa ("eb"), a rare genetic skin disease, has been accepted as an oral presentation at the 12th world congress on itch (wci), being held in miami on november 5-7, 2023. presentation details are below: abstract title: inm-755 cannabinol cream demonstrates anti-itch activity in patients with epidermolysis bullosa presenting author: alexandra mancini, senior vice president, clinical and regulatory affairs, inmed pharmaceutical inc. session: hot topics date/time: tuesday, november 7 at 4:08 pm et the phase 2 study: the phase 2 study was designed to evaluate the safety of inm-755 cbn cream, which consists of the control cream plus the active pharmaceutical ingredient cbn, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with eb.
INM Ratings Summary
INM Quant Ranking